Press release
John Hancock becomes the first life insurance carrier to offer access to GRAIL's multi-cancer early detection test to customers
Highlights power of strategic industry partnerships to promote preventive health and empower well-being BOSTON, Sept. 20, 2022 /PRNewswire/ -- Today, John
About this update from Illumina, Inc.
[{"type":"text","content":"Highlights power of strategic industry partnerships to promote preventive health and empower well-being \nBOSTON, Sept. 20, 2022 /PRNewswire/ -- Today, John Hancock, the US division of Toronto-based Manulife (NYSE: MFC), announced it is offering access to GRAIL's Galleri® multi-cancer early detection test to a pilot group of existing customers through the John Hancock Vitality Program, in collaboration with reinsurer Munich Re Life US. As the first life insurance carrier to make this breakthrough screening technology available, John Hancock is enabling eligible customers to take proactive steps to better understand and make more informed choices about their health.\n\n \n \n \n \n \n \n\n \nAccording to the American Cancer Society, more than 600,000 people die from cancer each year in the United States and many cancers show no symptoms until later stages, when treatment options may be limited.1 Early detection of cancer can improve cancer outcomes, yet today, many cancers are detected in late stages because only five types have recommended screenings — breast, cervical, colon, lung, and prostate cancers. \nJohn Hancock Vitality is available with the company's life insurance policies — offering education, support, incentives, and rewards to encourage customers to take everyday steps toward a longer, healthier, better life. The Galleri test, the newest feature to be added to the program for eligible customers, is a first-of-its-kind multi-cancer early detection blood test. In a clinical study, the Galleri test demonstrated the ability to detect a signal from more than 50 types of cancers, over 45 of which lack recommended screening tests. The test can also help determine where in the body cancer may be located, which can then guide diagnostic follow up.\n\"At John Hancock, we are deeply invested in helping our customers live longer, healthier, better lives. Almost everyone has experienced the devastating effects of cancer in some way and by making this early screening technology available, we can help change the cancer narrative for some of our customers,\" said Brooks Tingle, President and CEO of John Hancock Insurance. \"As a life insurer, we can use our unique position to make a powerful impact. As such, we are bringing together carriers, distributors, reinsurers, and innovative technology companies to transform our customers' ...